<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AB7C0822-BBCB-4C61-85EC-5D13C7A31759"><gtr:id>AB7C0822-BBCB-4C61-85EC-5D13C7A31759</gtr:id><gtr:name>MRC Laboratory of Molecular Biology</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 2QH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AB7C0822-BBCB-4C61-85EC-5D13C7A31759"><gtr:id>AB7C0822-BBCB-4C61-85EC-5D13C7A31759</gtr:id><gtr:name>MRC Laboratory of Molecular Biology</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 2QH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/60C77415-2DC0-4359-920E-6BEAA3C15CAB"><gtr:id>60C77415-2DC0-4359-920E-6BEAA3C15CAB</gtr:id><gtr:firstName>Terence</gtr:firstName><gtr:surname>Rabbitts</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U105178807"><gtr:id>B83DA31E-2F30-4981-8C0F-FB667B2BE58E</gtr:id><gtr:title>Modelling the role of chromosomal abnormalities in cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U105178807</gtr:grantReference><gtr:abstractText>Cancer arises by stepwise accumulation of mutations within somatic cells which can include macroscopic chromosomal abnormalities or point mutations. A number of such mutational events have been identified but analysis of the impetus and progression of cancer cannot be readily be studied in patients. We will continue to study laboratory mouse models that mimic human cancer development and their use in specific therapeutic situations. We will identify specific genes affected by the primary mutational events created in our model systems. In addition, mouse models that mimic specific human cancers will provide us with an authentic basis for establishing techniques to derive new therapeutic approaches and for pre-clinical testing of potential therapeutic entities.</gtr:abstractText><gtr:technicalSummary>The five year survival prospects for cancer patients vary considerably according to the type of cancer. Thus, there is a need to develop new reagents based on novel molecular targets (identified by molecular biology studies of cancer) and for assays to assess the efficacy of such reagents. Mouse models of cancer are of crucial importance not only to understand the genetic factors that influence the phenotypic characteristics of the disease but also to use as a basis for developing rational intervention strategies, that is for pre-clinical development of therapeutic strategies. Chromosomal translocations underlie many human leukaemias, sarcomas and epithelial tumours. There are several approaches modelling the effects of chromosomal translocations in mice and we have developed a system that fully recapitulates human translocations and generates both reciprocal products. This new system allows chromosomal translocations to occur de novo during mouse development using Cre-loxP recombination, mirroring the situation found in many human leukaemias. We plan to continue our studies of chromosomal translocations and other chromosomal abnormalities by studying mouse models of cancer based on molecular targets. These mouse models are particularly useful as experimental systems due to the homogeneous genetic background and general status on which they occur, providing a controlled situation for study (which human cancer cannot provide). We will use these models, and cell lines derived from them, to study the molecular consequences for tumour initiation and overt disease. This will be accomplished by experimental models in which selected proteins in the mouse cancers are targeted by intrabodies, antisense, siRNA or small molecules. Specific programmes will focus on the T cell oncogene LMO2 and additionally its role in tumour angiogenesis, on conditional mouse models of fusion gene-associated chromosomal translocations, on cloning techniques for non-reciprocal chromosomal translocation breakpoints and on further technology development involving use of intrabodies for intervention in cancer development and target validation. These approaches will eventually mark the end of the mouse model pre-clinical phase of our work and we plan to progress to the translation of these procedures into clinical use.</gtr:technicalSummary><gtr:fund><gtr:end>2008-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-01-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1448964</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>A4B4CCAB-2C01-47A4-B4E4-FA9B76DF9AFB</gtr:id><gtr:title>Leukaemia lineage specification caused by cell-specific Mll-Enl translocations.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbcad82585b37e480939c9b187de13c5"><gtr:id>fbcad82585b37e480939c9b187de13c5</gtr:id><gtr:otherNames>Cano F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>7ACF80626BA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>533166B2-11D6-436D-A445-527FA7D653BF</gtr:id><gtr:title>An antibody inhibitor of the LMO2-protein complex blocks its normal and tumorigenic functions.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5dd90bb0d9d71685286339c9d2846a35"><gtr:id>5dd90bb0d9d71685286339c9d2846a35</gtr:id><gtr:otherNames>Nam CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>5DF5C8D48DF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>19C690AC-4303-48D6-8FC9-41FAF9AE0DF5</gtr:id><gtr:title>The role of Slit-Robo signaling in the generation, migration and morphological differentiation of cortical interneurons.</gtr:title><gtr:parentPublicationTitle>Developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc08dcf8bead23f305d130f70f1a81fd"><gtr:id>bc08dcf8bead23f305d130f70f1a81fd</gtr:id><gtr:otherNames>Andrews W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0012-1606</gtr:issn><gtr:outcomeId>86194A4382F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AD9D9E6-6AF4-4196-9D53-734555416171</gtr:id><gtr:title>Preclinical modeling of cytosine arabinoside response in Mll-Enl translocator mouse leukemias.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbcad82585b37e480939c9b187de13c5"><gtr:id>fbcad82585b37e480939c9b187de13c5</gtr:id><gtr:otherNames>Cano F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>D321998B7DF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81C8CE95-756E-4711-AFF2-8807FF006226</gtr:id><gtr:title>MLL gene fusions in human leukaemias: in vivo modelling to recapitulate these primary tumourigenic events.</gtr:title><gtr:parentPublicationTitle>International journal of hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1058a716f43239e0a6553399ba518967"><gtr:id>1058a716f43239e0a6553399ba518967</gtr:id><gtr:otherNames>Rodriguez-Perales S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0925-5710</gtr:issn><gtr:outcomeId>E46195A636F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A776F521-588E-4E07-81E6-CCD157D2FEC0</gtr:id><gtr:title>Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1dac72a0ae4dc9317788012bda34c3cc"><gtr:id>1dac72a0ae4dc9317788012bda34c3cc</gtr:id><gtr:otherNames>Appert A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>2EAB61B9628</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7DC32193-B43C-4BA4-B598-F98F1410068A</gtr:id><gtr:title>Microdissection molecular copy-number counting (microMCC)--unlocking cancer archives with digital PCR.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/571a0cb275300a32e9185f4502768350"><gtr:id>571a0cb275300a32e9185f4502768350</gtr:id><gtr:otherNames>McCaughan F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>941D8B44C77</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B8B445E-59A4-4FE8-A9D4-F16CA243F652</gtr:id><gtr:title>Interrogation of genomes by molecular copy-number counting (MCC).</gtr:title><gtr:parentPublicationTitle>Nature methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe3de59f6b1000a2eb68fa245c302cf3"><gtr:id>fe3de59f6b1000a2eb68fa245c302cf3</gtr:id><gtr:otherNames>Daser A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1548-7091</gtr:issn><gtr:outcomeId>CA65EB3F39C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB658DBD-34C9-487A-A6BE-1195A30A2EC7</gtr:id><gtr:title>Interfering with protein-protein interactions: potential for cancer therapy.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9280b9f441ca1d50b85d73905fa208a8"><gtr:id>9280b9f441ca1d50b85d73905fa208a8</gtr:id><gtr:otherNames>Tanaka T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>pm_15100_10_18469527</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5714564-0239-4D6C-B136-47B23202EA78</gtr:id><gtr:title>Commonality but diversity in cancer gene fusions.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e51d5da25fa6ee3beb07f46b5f732106"><gtr:id>e51d5da25fa6ee3beb07f46b5f732106</gtr:id><gtr:otherNames>Rabbitts TH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>9BBC30DF757</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>585AE034-5858-48EC-937D-F7046744BE2C</gtr:id><gtr:title>Selection of complementary single-variable domains for building monoclonal antibodies to native proteins.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9280b9f441ca1d50b85d73905fa208a8"><gtr:id>9280b9f441ca1d50b85d73905fa208a8</gtr:id><gtr:otherNames>Tanaka T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>3323AC98013</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA870355-56B4-43DD-B745-D9F84A982689</gtr:id><gtr:title>Modeling chromosomal translocations using conditional alleles to recapitulate initiating events in human leukemias.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute. Monographs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b299705a31f260577325faad20fbe3e3"><gtr:id>b299705a31f260577325faad20fbe3e3</gtr:id><gtr:otherNames>Lobato MN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1052-6773</gtr:issn><gtr:outcomeId>F28C9D94AF9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29CB4E87-DF31-474E-9787-A75242C7745E</gtr:id><gtr:title>Functional intracellular antibody fragments do not require invariant intra-domain disulfide bonds.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9280b9f441ca1d50b85d73905fa208a8"><gtr:id>9280b9f441ca1d50b85d73905fa208a8</gtr:id><gtr:otherNames>Tanaka T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>EBE893338DB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D693F369-5BB8-44B8-8470-8238427D4642</gtr:id><gtr:title>Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9280b9f441ca1d50b85d73905fa208a8"><gtr:id>9280b9f441ca1d50b85d73905fa208a8</gtr:id><gtr:otherNames>Tanaka T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>1F317C3216F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E56DF39-D502-4B0A-8A35-FB4B301EBA3F</gtr:id><gtr:title>Selection of human single domain antibodies recognizing the CMYC protein using enhanced intracellular antibody capture.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c5dd22e69937cc91b3f56ac7eae76ea"><gtr:id>9c5dd22e69937cc91b3f56ac7eae76ea</gtr:id><gtr:otherNames>Zeng J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>56d80ea454d3b7.60224734</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U105178807</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>